REG - ReNeuron Group plc - Notification of Interim Results

ReNeuronAnnouncement

20/11/2018 14:00

RNS Number : 9315H
ReNeuron Group plc
20 November 2018
 


 
 



AIM: RENE






20 November 2018



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Notification of Interim Results
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2018 on Friday 14 December 2018.
 
A meeting for analysts will be held at 9.30am on the morning of 14 December 2018 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
 
For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am on the day of the results:
 
http://webcasting.buchanan.uk.com/broadcast/5bf3e08d1a82c37e3088a28b
 
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
 
 
ENDS
 
Enquiries:
 



ReNeuron


+44 (0) 20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer








 
Buchanan


 
+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham


















Stifel Nicolaus Europe Limited
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)


+44 (0) 20 7710 7600




N+1 Singer Advisory LLP
Mark Taylor (Joint Broker)


 
+44 (0) 20 7496 3000



 
About ReNeuron
 
ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  
 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBMBTTMBATBFP